(18)F-FDG PET/CT in lymphoma: Has imaging-directed personalized medicine become a reality?
(18)F-FDG PET/CT in lymphoma: Has imaging-directed personalized medicine become a reality?
PET/CT using (18)F-FDG is an essential part of the management of patients with lymphoma. Efforts to standardize PET acquisition and reporting, including the 5-point Deauville scale, have enabled PET to become a surrogate for treatment success or failure in common lymphoma subtypes. This review summarizes the key clinical-trial evidence that supports PET-directed personalized approaches in lymphoma. PET-guided therapy has improved outcomes in Hodgkin lymphoma, using less chemotherapy and more selective radiotherapy. Attempts to intensify chemotherapy in aggressive non-Hodgkin lymphomas have, however, proved ineffective in patients treated with rituximab and chemotherapy. Trials are under way to determine whether PET can obviate consolidation radiotherapy in patients with diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. More recently, PET has been reported to be a reliable predictor of outcome in follicular lymphoma requiring treatment, and prospective trials to test PET-guided therapy in this disease are anticipated.
Fluorodeoxyglucose F18, Hodgkin Disease, Humans, Lymphoma, Non-Hodgkin, Positron Emission Tomography Computed Tomography, Precision Medicine, Journal Article, Review
1539-1544
Barrington, Sally F.
fb047bda-27e7-4082-b741-c41ef52aa53c
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
October 2017
Barrington, Sally F.
fb047bda-27e7-4082-b741-c41ef52aa53c
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Barrington, Sally F. and Johnson, Peter W.M.
(2017)
(18)F-FDG PET/CT in lymphoma: Has imaging-directed personalized medicine become a reality?
The Journal of Nuclear Medicine, 58 (10), .
(doi:10.2967/jnumed.116.181347).
Abstract
PET/CT using (18)F-FDG is an essential part of the management of patients with lymphoma. Efforts to standardize PET acquisition and reporting, including the 5-point Deauville scale, have enabled PET to become a surrogate for treatment success or failure in common lymphoma subtypes. This review summarizes the key clinical-trial evidence that supports PET-directed personalized approaches in lymphoma. PET-guided therapy has improved outcomes in Hodgkin lymphoma, using less chemotherapy and more selective radiotherapy. Attempts to intensify chemotherapy in aggressive non-Hodgkin lymphomas have, however, proved ineffective in patients treated with rituximab and chemotherapy. Trials are under way to determine whether PET can obviate consolidation radiotherapy in patients with diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. More recently, PET has been reported to be a reliable predictor of outcome in follicular lymphoma requiring treatment, and prospective trials to test PET-guided therapy in this disease are anticipated.
This record has no associated files available for download.
More information
Accepted/In Press date: 4 August 2017
e-pub ahead of print date: 10 August 2017
Published date: October 2017
Keywords:
Fluorodeoxyglucose F18, Hodgkin Disease, Humans, Lymphoma, Non-Hodgkin, Positron Emission Tomography Computed Tomography, Precision Medicine, Journal Article, Review
Identifiers
Local EPrints ID: 416087
URI: http://eprints.soton.ac.uk/id/eprint/416087
ISSN: 0161-5505
PURE UUID: aa7303ba-37e0-4fe6-8ff0-bf3c24513154
Catalogue record
Date deposited: 01 Dec 2017 17:30
Last modified: 16 Mar 2024 03:00
Export record
Altmetrics
Contributors
Author:
Sally F. Barrington
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
